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This paper describes the production, purification, and immobilization of L-asparaginase II (ASNase II) in chitosan
nanoparticles (CSNPs). ASNase II is an effective antineoplastic agent, used in the acute lymphoblastic leukemia
chemotherapy. Cloned ASNase II gene (ansB) in pAED4 plasmid was transformed into Escherichia coli BL21pLysS
(DE3) competent cells and expressed under optimal conditions. The lyophilized enzyme was loaded into CSNPs
by ionotropic gelation method. In order to get optimal entrapment efficiency, CSNP preparation, chitosan/
tripolyphosphate (CS/TPP) ratio, and protein loading were investigated. ASNase II loading into CSNPs was
confirmed by Fourier transform infrared (FTIR) spectroscopy, and morphological observation was carried out by
transmission electron microscopy. Three absolute CS/TPP ratios were studied. Entrapment efficiency and loading
capacity increased with increasing CS and TPP concentration. The best ratio was applied for obtaining optimal
ASNase II-loaded CSNPs with the highest entrapment efficiency. Size, zeta potential, entrapment efficiency, and
loading capacity of the optimal ASNase II-CSNPs were 340 ± 12 nm, 21.2 ± 3 mV, 76.2% and 47.6%, respectively.
The immobilized enzyme showed an increased in vitro half-life in comparison with the free enzyme. The pH
and thermostability of the immobilized enzyme was comparable with the free enzyme. This study leads to a
better understanding of how to prepare CSNPs, how to achieve high encapsulation efficiency for a high
molecular weight protein, and how to prolong the release of protein from CSNPs. A conceptual understanding
of biological responses to ASNase II-loaded CSNPs is needed for the development of novel methods of
drug delivery.
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L-Asparaginase II (ASNase II) is an enzyme that is
widely used for the treatment of hematopoietic diseases
such as acute lymphoblastic leukemia. The enzyme is
able to destroy asparagine-dependent tumors by
degrading circulating L-asparagine and destroying
malignant cells [1,2]. However, native ASNase II is as-
sociated with a high incidence of allergic reactions. Due
to the formation of neutralizing antibodies, the half-life
of circulating ASNase II (18 to 24 h) can be shortened* Correspondence: Khosrow@rvsri.ac.ir
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in any medium, provided the original work is pto approximately 2.5 h [3]. Moreover, it is susceptible
to proteolytic degradation by the proteases of the host
organism. Much effort has been devoted to develop
methods to avoid such side effects as well as to increase
its in vivo half-life. For example, ASNase II has been
chemically modified by polyethyleneglycol [4], poly-(D,
L-alanine) [5], and dextran [6].
In the recent years, nanotechnology has shown a
significant promise in the preparation of immobilized
enzymes. Immobilization of enzymes onto biopolymer
nanoparticles may result in some benefits, such as impro-
ving their stability to pH and temperature, as well as
resistance to proteases and other denaturing compounds.
Candidate carrier biopolymers should exhibit chemicalan Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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homogeneous molecular weight (MW) distribution, and
adequate functional groups for binding to biomolecules
with high loading capacity. They exhibit several drug loa-
ding mechanisms including electrostatic attractions,
hydrophobic interactions, and covalent binding. They
can form a matrix or membrane that can slow drug
release over a prolonged period, avoiding repetitive
dosing. However, one should bear in mind that covalent
coupling of enzymes to polymers may result in con-
formational alterations, pharmacokinetic modifications,
and a significant decrease in enzymatic activity. Exa-
mples of such biopolymer nanoparticles that ASNase II
has already been incorporated in are liposomes [7], poly
(D,L-lactide-co-glycolide) (PLGA) [8], and hydrogel-
magnetic nanoparticles [9].
Chitosan (CS), produced by alkaline N-deacetylation of
chitin, is another natural polymer that has good physico-
chemical (reactive OH and NH2 groups), as well as
biological properties. It is composed of glucosamine and
N-acetylglucosamine monomers linked by β [1-4] glyco-
sidic bonds. CS is hydrophilic and soluble in acidic solu-
tions by protonation of the amine groups. It is degraded
by enzymes such as lysozymes, some lipases, and prote-
ases. CS is a biologically safe, non-toxic, biocompatible,
and biodegradable polysaccharide [10]. Current research
with CS focuses on its use as a novel drug, gene, peptide,
and vaccine delivery vehicle and as a scaffold for targeted
drug delivery and tissue engineering applications [11,12].
Two groups of cross-linkers are usually employed to
obtain CS particles. One group, such as glutaraldehyde
and glucomannan, cross-links through covalent bonds
leading to quite stable matrixes. The other group is ionic
cross-linkers that cross-link through ionic gelation and
electrostatic interactions between the positively charged
chitosan chains and polyanions. The polyanion most
commonly used for the ionic cross-linking is tripolypho-
sphate (TPP), which is non-toxic. Due to the proved
toxicity of glutaraldehyde and other organic molecules
used in the synthesis of gels covalently stabilized, only
the second synthesis technique (ionic gelation) can be
used for pharmaceutical applications.
Bodmeier et al. [13] and Calvo et al. [14] used an iono-
tropic gelation method to prepare CS particles with sizes
ranging from micron to submicron for the first time,
and this is a currently widely used method for preparing
CSNPs. In this method, an anionic cross-linking agent is
introduced into an aqueous solution of CS in acetic acid.
The cross-linking structure of the CS/TPP system is
mainly determined by the reaction between the amino
groups of CS and TPP ions, and this reaction depends
strongly on the associated pH [15,16]. Alteration in the
parameters such as cross-linker concentration, drug/
polymer ratio, and processing conditions affects themorphology of CSNPs and the release rate of the loaded
drug [17,18].
Formulation development and optimization is a very
critical process in the design and manufacture of any
therapeutic drug. Depending on the design and delivery
aims for a particular drug, the process requires several
in vitro and in vivo study stages. Generally, the in vitro
property is the rate or extent of drug dissolution and its
release, whereas the in vivo study involves the plasma
drug concentration, absorption, body interactions, and
any possible side effects. The purpose of the in vitro
study in the early stage of nanodrug development is to
investigate the optimum formulation, evaluate the active
ingredient, and assess any minor changes for drug deve-
lopment. The aim of the present work was to assess the
in vitro preparation of ASNase II-loaded CSNPs cross-
linked with TPP and to evaluate their efficacy for the
entrapment and controlled release of the protein. The




The following materials were used: BL21 pLysS (DE3)
strain (Novagen, Cat. No.: 69451–3, Darmstadt, Germany),
pAED4 (BV Tech, Sofia, Bulgaria), isopropyl β-D-1-
thiogalactopyranoside or IPTG (Sigma-Aldrich Cat. No.:
I6758, St. Louis, MO, USA), Luria Bertani broth or LB
broth (Merck, Cat. No.: 1.10285.0500, Whitehouse Station,
NJ, USA), diethylaminoethyl (DEAE)-Sepharose Fast Flow
(Amersham, Cat. No.: 17-0709-01, Amersham, UK), Sepha-
dex G-75 (Sigma-Aldrich, Cat. No.: G7550), L-asparagine
(Sigma-Aldrich, Cat. No.: A0884), Nessler's reagent (Sigma-
Aldrich, Cat. No.: 72190), and CS (low molecular weight (%
deacetylation 75% to 85%, viscosity 20 to 300 cP, average
MW~50 kDa), Sigma-Aldrich; Cat. No.: 448869), sodium
tripolyphosphate (Sigma-Aldrich, Cat. No.: 238503).
ASNase II production, extraction, and purification
According to our optimized protocol for overproduc-
tion of recombinant protein [19], ASNase II (EC
3.5.1.1) was expressed in transformed Escherichia coli
BL21 pLysS (DE3). The periplasmic ASNase II was ex-
tracted from the bacterial pellet using modified alkaline
lysis method [19]. The extract was clarified by centrifu-
gation for 30 min at 30,000 × g at 4°C, and the super-
natant was filtered through a 0.45-μm sterile filter. A
single-step purification of ASNase II was performed by
loading the filtrate sample onto the DEAE-Sepharose
Fast Flow column (5 cm × 15 cm) pre-equilibrated with
phosphate buffer (0.01 mM, pH 7.0). After removing
the unbound proteins from the column by passing
phosphate buffer, NaCl gradient from 50 to 200 mM
was applied to the column at a flow rate of 4 ml/min.
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vity (U/ml) and protein content (mg/ml). The purity of
ASNase II was judged using sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) (15%)
stained with Coomassie brilliant blue. The fractions
with the higher ASNase II activity were pooled and
analyzed for total activity (U), total protein level (mg),
and specific activity (U/mg).
The purified solution from the previous step was
desalted using Sephadex G-75 column (3.0 × 70 cm) pre-
equilibrated with double-distilled water (DDW) at a flow
rate of 3 ml/min. The most active fractions were pooled
and concentrated by lyophilization (−50°C) and the
protein powder was stored at 4°C.
Estimation of ASNase II activity
The activity of ASNase II was assayed using the Ness-
ler method [20]. A reaction mixture contained 0.5 ml
Tris–HCl buffer (0.1 M, pH 8.5), 0.25 ml L-asparagine
(10 mM in Tris–HCl buffer), and 25 μl of the enzy-
matic solution. After 15 min of incubation at 37°C, the
reaction was terminated by the addition of 0.25 ml of
15% trichloroacetic acid (TCA). The liberated ammo-
nia was determined by adding 0.25 ml of Nessler's
reagent. The absorbance was recorded at 425 nm after
10 min. The absorbance values were converted to
micromoles of ammonia using a standard curve pre-
pared with ammonium sulfate. One unit of enzyme
activity (IU) was defined as the amount of enzyme
required to release 1 μmol of ammonia per minute
under standard assay conditions.
Estimation of protein concentration
Protein concentration was estimated with Folin phenol
reagent (Lowry method) using bovine serum albumin as
a standard [21].
Preparation of CSNPs
CSNPs were prepared based on the ionotropic gelation
method [22] with a small modification. The method is
based on electrostatic interactions between the amine
group of CS and the negatively charged group of TPP as
a polyanion. During the process involving chemical re-
action, CS undergoes ionotropic gelation and precipi-
tates to form spherical particles that are distinguishable
by opalescence of solution.
Low molecular weight CS was dissolved in DDW
containing 1.2% acetic acid to a concentration of 0.5%
(w/v) as stock solution. The isoelectric point of ASNase
II and pKα of CS are 4.9 [23] and 6.5 [24,25], respec-
tively. The pH of the CS solution was adjusted to 5.7 by
NaOH as the mean pH point. TPP with the concentra-
tion of 0.5% (w/v) in DDW was prepared as the stocksolution. Both solutions were filtered through a 0.25-μm
sterile filter.Preparation of ASNase II-CSNPs
ASNase II activity against CS and TPP
In order to determine the individual effect of each CS
and TPP on ASNase II activity, 1 ml CS solution (0.2%
(w/v), pH ~ 5.7) and 1 ml TPP solution (0.1% (w/v),
pH ~ 8.5) were prepared from stocks. One milligram of
lyophilized ASNase II was added to each solution, and
both of them were slowly shaken for 15 min. The per-
centage of the preserved activity for both solutions
was calculated based on the activity of untreated ASNase
II (1 mg/ml), which was taken as 100%.Two ways of preparation of the ASNase II-loaded CSNPs
The preparation of the ASNase II-loaded CSNPs via the
ionotropic gelation method was examined in two ways.
In the first approach, 1 mg of lyophilized protein was
mixed with 1 ml of TPP solution (0.1% (w/v)), and the
mixture was added dropwise to 1 ml of CS solution
(0.2% (w/v)) with stirring using a magnetic stirrer. In the
second method, 1 mg of lyophilized protein was mixed
with 1 ml of CS solution (0.2% (w/v)), and TPP (0.1%
(w/v)) was added dropwise to the protein/CS mixture
with stirring. After 10 min of stirring, each opalescent
solution was centrifuged (25,000 × g, 25°C for 30 min),
and the amounts of the free protein in each supernatant
were measured in order to analyze the entrapment
efficiency.Optimization of CS and TPP concentrations
To optimize the CS/TPP ratio based on particle size and
the entrapment efficiency, various CS concentrations
(0.2%, 0.3%, and 0.4% (w/v)) were prepared from the
stock solution. The concentrated TPP solution (0.5%
(w/v)) was used in order not to dilute the CS/ASNase II
mixture more than necessary. From this stock solution,
different volumes of TPP solution (Table 1) were added
dropwise (10 μl per 10 s interval) to 1 ml of each CS
concentration (containing 1 mg lyophilized ASNase II)
with stirring (about 800 rpm), with particular care taken
to avoid foam formation. In addition to the applied vo-
lumes of TPP, Table 1 shows the final concentrations of
the added TPP (%w/v). All procedures were carried out
at room temperature (25°C). After 10 min of stirring, the
particles were collected by centrifugation at 25,000 × g,
25°C for 30 min in 50-μl glycerol bed. The supernatants
were separated to estimate the entrapment efficiency
(%). The pellets of the particles in glycerol were sus-
pended in 1 ml of distilled water to determine the
average sizes (nm).
Table 1 Chitosan concentrations, TPP volumes from TPP
stock solution (0.5%w/v), and final TPP concentrations in
final prepared nanoparticle suspensions
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The stable and suitable CS/TPP ratio from the previ-
ous step was selected in order to investigate the opti-
mal entrapment efficiency and loading capacity of
CSNPs, loaded with five different amounts of protein
(1, 2, 3, 4, and 5 mg). Nanoparticles were prepared ac-
cording to the procedure given above by adding a cer-
tain amount of lyophilized ASNase II in 1 ml of optimal
CS solution. After centrifugation, the supernatants were
separated to estimate the entrapment efficiency. The
pellets of the particles in glycerol were suspended in 1 ml
of DDW and dispersed by sonication. The size (nm), zeta
potential (mV), protein content (mg), entrapment
efficiency (%), and loading capacity (%) of the particles
were determined.
Entrapment efficiency estimation
In order to determine the entrapment efficiency of the
nanoparticles, it was necessary to detect by the Lowry
method [21] the amount of free enzyme in the clear
supernatant. The ASNase II entrapment efficiency was
calculated using the following equation:
Entrapment efficiency %ð Þ ¼
h
ðTotal protein used in formulation
−Free amount of proteinÞ




The loading capacity was defined as the ratio of the
amount of ASNase II entrapped and the weight of nano-
particles and calculated according to the following math-
ematical expression:
Loading capacity %ð Þ ¼ ðMass of protein content of the
nanoparticles=Weight of nanoparticlesÞ
100Characterization of ASNase II-loaded CSNPs
Particle size and zeta potential of ASNase II-CSNPs
The particle size, size distribution (polydispersity index
(PDI)), and zeta potential of particles were measured by
Zetasizer (Malvern Instruments, Worcestershire, UK),
based on the dynamic light scattering (DLS) technique.
The mean particle size was approximated as the z-aver-
age diameter and the width of the distribution as the
PDI. DLS measurements were performed at 25°C with a
detection angle of 90°. All measurements were pre-
formed in triplicate, and the results were reported as
mean ± standard deviation.
Fourier transform infrared spectroscopy
Fourier transform infrared (FTIR) spectroscopy (Bruker,
Ettlingen, Germany) was used to characterize bonding
characteristics of the lyophilized ASNase II, CS, CSNPs,
and ASNase II-CSNPs.
Morphological observations
Examinations of surface morphology and size distribu-
tion for CSNPs and ASNase II-loaded CSNPs were per-
formed using a transmission electron microscope (TEM)
(Philips CM30, Eindhoven, The Netherlands). About 5 μl
of the nanoparticle solution was placed on a copper grid
and stained with 2% (w/v) phosphotungstic acid.
In vitro ASNase II release
ASNase II release from the matrix complex was eva-
luated in three solutions of glycerol (5%)-phosphate-
buffered saline (PBS) solution (pH 7.4), PBS solution
(pH 7.4), and DDW containing 5% glycerol (pH 7.0).
ASNase II-loaded CSNPs with the highest protein loa-
ding capacity were suspended in each of these solutions
and incubated at 37°C. At predetermining time points,
nanoparticles were collected with a centrifuge (25,000 × g,
30 min and 25°C). The supernatant was removed for
protein content assay.
The percentage of leakage from the nanoparticles was
calculated using the following equation:
%L ¼ Mo = Með Þ  100
where %L represents the percentage of leakage, Mo is
the mass of ASNase II in the supernatant, and Me is the
mass of entrapped ASNase II.
Effect of pH on enzyme activity and stability
The activities of the immobilized and free ASNase II
were evaluated at different pH values in the range
between pH 6.5 and 10 adjusted with Tris–HCl (0.1 M).
Figure 1 SDS-PAGE (15%) analysis of ASNase II purification
using DEAE-Sepharose. Lane 1: protein marker. Lane 2: Crude
extract of E. coli by alkaline lysis. Lanes 3 to 11: purified ASNase II
eluted from the DEAE-Sepharose column in selected fractions.
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and free enzymes were incubated for 24 h at 4°C ± 1°C
at different pH values (pH 6 to 10) in the absence of the
substrate, and the residual activity was determined. The
percentage of residual activities was calculated based on
the untreated control activity, which was taken as 100%.
Effect of temperature on enzyme stability
Thermostability studies were carried out by pre-incubating
the immobilized and free ASNase II at different tempera-
tures (37°C, 45°C, 50°C, 60°C, 70°C, 80°C, and 90°C) for
60 min, followed by cooling. The percentage of residual
activities was determined and calculated based on the
untreated control activity, which was taken as 100%.
Half-life determination of the free and immobilized
ASNase II
The solutions of Tris–HCl (0.1 M, pH = 8.5), DDW-
glycerol (5%), and PBS-glycerol (5%) were considered for
measuring the half-life of the free and immobilized
enzyme. Solutions of the immobilized and free enzyme
were slowly homogenized and incubated at 37°C to measure
the half-life of both. At the time interval of 1, 3, 6, and 24 h,
a sampling was done without replacement for the deter-
mination of enzymatic activity.
Results and discussion
Production and purification of ASNase II
As mentioned above, protein expression was carried out
under conditions that were previously optimized in our
laboratory. The extract prepared by alkaline lysis was
passed through a DEAE-Sepharose Fast Flow column.
Table 2 shows a summary of the results, before and after
purification. The total specific activity increased from
18.6 to 111.5 U/mg for the filtrate and the final prepa-
ration, respectively. About 81.5% of the original enzyme
activity was recovered with a purification fold of 6. Puri-
fication was examined by SDS-PAGE following Coomas-
sie brilliant blue staining (Figure 1). It revealed only a
single distinctive protein band for the pure preparation
of ASNase II with an apparent molecular weight of
35 kDa, corresponding to a monomer of the denatured
enzyme. All known types of ASNase II are active as
homotetramers with molecular mass of approximately
140 kDa, arranged as 222-symmetric assemblies around
three mutually perpendicular dyads. The closest inter-






Before purification (filtrate) 80 786.4
After purification (DEAE-Sepharose) 187 106.7
aYield = Total activity after purification/Total activity before purification.subunits B and D) lead to the formation of two intimate
dimmers within which the four non-allosteric catalytic
centers are created. Such formation of tetramers, for re-
asons that are not completely clear, appears to be essential
for the catalytic ability of ASNase II [26,27].
Chloride (which would interfere with TPP in prepa-
ration of ionotropic nanoparticles) was eliminated from
the DEAE-chromatographic product by Sephadex G-75
and the protein was lyophilized. At the high ionic
strengths, the CS-TPP binding would be weakened to
the point that the nanoparticles would cease to form
[28], due to the competitive reaction between Cl− and
TPP ions for NH3
+.
Preparation of ASNase II-loaded CSNPs
ASNase II activity in CS and TPP solutions
Both CS and TPP have their characteristic charge and
may likely affect ASNase II stability and activity. The be-
havior of ASNase II in the CS and TPP solutions was indi-
vidually investigated before preparation of nanoparticles.
The percentages of the preserved ASNase II activity in CS
and TPP were 85% and 80% of the activity of untreated
enzyme, respectively. This result can be explained from
the standpoint of pH. As will be mentioned below, the
optimum pH for the activity of free ASNase II is between
8.5 and 9 and enzyme activity decreases to about 86% at
pH~ 6.5. Most of the decrease in ASNase II activity in the








14,604.48 18.57 100 1
11,896.8 111.5 81.4 6.0
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of the resulted solution was about 8.5 which is close to the
optimum pH of free ASNase II activity. Thus, the decrease
in ASNase II activity may be attributed to the effect of
TPP on ASNase II, such as repulsion between the negative
charges on TPP and ASNase II, the latter being negatively
charged at pH 8.5.
Two ways for ASNase II-CSNP preparation
We compared the two methods of preparation of
ASNase II-loaded CSNPs through ionotropic gelation
method. The entrapment efficiency, size, and zeta poten-
tial of the nanoparticles prepared through adding
ASNase II-TPP into CS solution were 61%, 143 ± 5 nm,
and +35.4 ± 2 mV, whereas they were 68%, 140 ± 4 nm,
and +34.9 ± 2 mV when TPP was added into ASNase II-
CS solution. No significant differences were seen in the
size and zeta potential between the two groups of nano-
particles, but the entrapment efficiency of the nanoparti-
cles which resulted from adding TPP into ASNase II-CS
solution was significantly higher than when ASNase II-
TPP was added into the CS solution. This observation
can be explained by possible interactions of ASNase II
molecules with CS polymer before the addition of the
cross-linker.
Since proteins are large macromolecules with flexible
structure and are able to fold and unfold at different
conditions, their interactions with long cationic CS chain
and the resulting encapsulation can be complicated,
depending on 3-D conformation, electrostatics, and the
condition of solution. The polycationic CS chain has a
flexible helical conformation in the relatively acidic solu-
tion (pH ~ 5.7), due to electrostatic repulsion forces
which exist among the protonated amine groups, either
within or between polymer chains. The CS chains pos-
sess three functional groups for chemical interaction:
two hydroxyl groups (primary or secondary) and one
primary amine. The negatively charged carboxyl groups
on the surface of ASNase II could form electrostatic
interactions with the positively charged amine groups
and make hydrogen bonds with the hydroxyl groups of
the CS chains. Such attachments of a spherical protein
molecule did not completely suppress the positive
surface charge of CS molecules. Therefore, a high pro-
portion of amine groups on the CS chain might remain
free and ready to form cross-links with TPP [29].
As CS is a highly charged polymer at pH ~ 5.7 (below
its pKα ~ 6.5), it tends to form ion pairs with TPP as a
polyvalent anion. At acidic pH, ionotropic cross-linking
is the only way of neutralization of protonated CS by
TPP ions. Dissolved sodium tripolyphosphate in water
dissociates to give both hydroxyl and TPP ions (pH ~
8.5). OH− and TPP ions in the acidic CS solution could
compete to interact with the -NH3
+ of CS, but OH− ionswould be immediately neutralized by H+ ions and
increase the pH of the CS solution. Therefore, by adding
TPP, a competition would occur between ionotropic
cross-linking by a polyanion and neutralization through
deprotonation of CS. Ionotropic cross-linking is an
important property which is broadly used in ionotropic
gelation processes.
The mild effect of CS on the activity of ASNase II and
the higher entrapment efficiency indicated adding TPP
into the protein-CS solution as the selected way for
nanoparticle preparation in the next steps.
Optimization of CS and TPP concentrations
CSNPs were prepared by certain amounts of CS
(containing 1 mg ASNase II) and TPP. Increasing TPP
volume or decrease in CS/TPP ratio led to increased
turbidity, indicating a shift in the size variation of the
particles to larger dimensions. Optimization of the CS/
TPP ratio revealed that when this ratio declined to
0.2/0.06, 0.3/0.08, and 0.4/0.11, high turbidity appeared
from the increased aggregation of the nanoparticles.
Thus, the CS/TPP ratios of 0.2/0.06, 0.3/0.08, and 0.4/
0.11 (Table 1) were discarded because of aggregation
which was confirmed microscopically [14,30].
Nanoparticle aggregation occurs under circumstances
such as the rise in pH of suspension [31], inadequate
speed of homogenization, or high level of cross-linker
[29]. López et al. [31] suggested that since the pKα value
of the chitosan is close to the neutral pH, particles spon-
taneously aggregate in slightly basic pH, where they
become completely uncharged. The final pH of the pre-
pared ASNase II-loaded CSNP suspensions was between
6.2 and 6.3 in all CS/TPP ratios, which was lower than
the pKα of chitosan. Moreover, increase in TPP concen-
tration might be a more important agent for particle ag-
gregation via cross-linking, as was observed through a
raise in TPP volume. Aggregation might be prevented by
using a high-speed homogenizer or by sonication during
CSNP preparation, but such approaches would lead to
inactivation of ASNase and thus could not be used.
Table 3 shows that the average size of the particles
increased with a lower CS/TPP ratio (PDI < 0.4) and was
positively associated with ASNase II entrapment effi-
ciency. Entrapment efficiency was the highest (70%)
when the concentration of CS/TPP was 0.4/0.095. These
results might be due to an increased number of inter-
acting units at higher polymer concentrations and to
cross-linker levels that lead to the observed increase in
particle size and entrapment efficiency [32,33].
Optimization of protein loading
Although a general definition identifies nanoparticles as
having dimensions below 100 nm, in the area of drug
delivery, large nanoparticles (size > 100 nm) may be
Table 3 The size, polydispersity index (PDI < 5 and
unimodal size distribution), and entrapment efficiency of
nanoparticles
CS (%w/v)/TPP (%w/v) Size (nm) PDI EE (%)
0.2/0.04 138 ± 7 0.35 59.1
0.3/0.06 180 ± 8 0.35 60.2
0.4/0.08 224 ± 10 0.44 62.7
0.2/0.05 187 ± 9 0.43 64.0
0.3/0.075 209 ± 11 0.47 67.3
0.4/0.095 247 ± 10 0.4 70.8
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the particles [34]. According to a working group of the
European Science Foundation in 2004, nanoscale in
nanomedicine was taken to include active components
or objects in the size range from 1 nm to 100 s of nano-
meters [35]. Accordingly, the CS/TPP ratio of 0.4/0.095
with the highest average entrapment efficiency of 70%
and an average size of 247 nm (from the previous step)
was applied to optimize protein loading with five dif-
ferent amounts of the lyophilized ASNase II (1, 2, 3, 4,
and 5 mg). By adding 5 mg of the lyophilized protein
in 1 ml of CS 0.4% (w/v), a small amount of insoluble
precipitate was formed. Therefore, the 5 mg/ml protein
concentration was excluded from further study. The
average size, zeta potential, protein content, entrap-
ment efficiency, and loading capacity of the ASNase
II-loaded CSNPs are displayed in Table 4. At the con-
stant CS/TPP ratio, it seems that there is no sudden
change in the particle size. The protein concentration
increased from 1 to 4 mg/ml, but about 8% size en-
largement of nanoparticles was observed in each step.
The final size of nanoparticles with 4 mg/ml of
ASNase II was about 36% larger than the correspond-
ing size of nanoparticles in 1 mg/ml.
Entrapment efficiency, yield, and loading capacity of
the nanoparticles were increased through an increase in
the amount of applied protein. These results are in
agreement with those of Yoshida et al. [36] who studied
the adsorption of BSA onto ionically cross-linked CS.Table 4 The characteristics of ASNase II-loaded CSNPs prepar
different amounts of lyophilized ASNase II
Lyophilized protein (mg) Size (nm) PDI Zeta potential (m
1 250 ± 11 0.48 +35.5 ± 2
2 262 ± 10 0.38 +30.7 ± 2
3 295 ± 9 0.27 +24.1 ± 3
4 340 ± 12 0.42 +21.2 ± 3
5 ND ND ND
PDI < 5 and unimodal size distribution. ND, not determined (the physicochemical ch
suitable for further study); data shown are the mean ± standard deviation.According to these results, the negatively charged pep-
tide and protein molecules are supposed to be encapsu-
lated more efficiently in a cationic CS polymer. At the
pH 5.7, the negatively charged ASNase II molecules (pI
~ 4.9) with their spherical structure could compete with
TPP ions to electrostatically react with CS. In other
words, ASNase II not only did not interfere with the for-
mation of CSNPs but also might have helped to form
CSNPs. The zeta potentials of ASNase II-loaded CSNPs
were decreased from +35.5 ± 2 to +21.2 ± 3 mV when
the protein contents of CSNPs were increased. Decline
in the zeta potential could be explained by the reduction
in -NH3
+ groups on the CS because of further protein
loading. In addition to TPP, the negative groups on the
surface of ASNase II were counteracted with the posi-
tively charged -NH3
+ groups of CS during the cross-
linking process. Moreover, TPP could counteract with
the positively charged -NH3
+ groups on the surface of
ASNase II and compact the enzyme both inside and on
the surface of the particle. Particles possessing a zeta
potential of about 20 to 25 mV may sometimes be
considered relatively stable [37]. However, having a suf-
ficient zeta potential is extremely important for the role
of nanoparticles as carriers for drugs or proteins; the
nanoparticles must be capable of ionically holding active
molecules or biomolecules. Nanoparticle used for the
final characterization were loaded with 4 mg lyophilized
ASNase II.
Fourier transform infrared spectrometry analysis
The FTIR spectra for ASNase II (a), CS (b), CSNPs (c),
and ASNase II-loaded CSNPs (d) are shown in Figure 2.
The peaks at 3,291 cm−1 in the ASNase II spectrum (a)
and at 3,288 cm−1 in the CS spectrum (b) relate to the
stretching of O-H and N-H bonds. In the CSNPs
spectrum (c), a shift from 3,288 to 3,299 cm−1 is seen and
the peak at 3,299 cm−1 becomes more intense; this indi-
cates the -NH3
+ interactions with TPP. A corresponding
peak in the ASNase II-loaded CSNPs (d) at 3,294 cm−1
becomes wider; this effect is attributable to the participa-
tion of ASNase II in hydrogen bonding and -NH group
interactions [38]. In CSNPs, a new sharp peak appears ated by CS/TPP 0.4%/0.095% (w/v) and loaded with
V) Protein content (mg) EE (%) Yeild (mg) LC (%)
0.701 ± 0.011 70.1 3.02 23.3
1.464 ± 0.05 73.2 4.18 35.1
2.244 ± 0.105 74.8 5.5 40.8
3.048 ± 0.07 76.2 6.4 47.6
ND ND ND ND
aracteristic of the nanoparticles prepared from 5 mg of protein was not
Figure 2 FTIR spectra of (A) ASNase II, (B) CS, (C) CSNPs, and
(d) ASNase II-loaded CSNPs.
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bration shifts to 1,536 cm−1. We suppose that the phos-
phoric groups of TPP are linked with -NH3
+ group of CS;
inter- and intra-molecular interactions are enhanced in
CSNPs [39]. A shift from 1,027 cm−1 to the sharper peak
at 1,032 cm−1 corresponds to the stretching vibration of
the P =O groups in CSNPs. Two peaks at 1,636 cm−1
(amide I bending) and 1,544 cm−1 (amide II bending) in
ASNase II-loaded CSNPs correspond to the high intensity
peaks at 1,638 and 1,536 cm−1 in the ASNase II spectra;
this result proves successful loading of ASNase II in
CSNPs and also indicates some interactions between CS
with TPP and ASNase II [40].
Morphology studies for the nanoparticles
Figure 3 shows the TEM images of CSNPs and ASNase
II-loaded CSNPs. From the TEM images, both CSNPs
(Figure 3A) and ASNase II-loaded CSNPs (Figure 3B)
are spherical and exist as discrete spheres, along with a
few partial cohesive spheres. The dark core of nanoparti-
cles is due to the fact that the staining reagent has pene-
trated through the particle. In Figure 3A, a fairly
uniform size (the average size 250 ± 11 nm, PDI ~ 0.48)
distribution and the smooth border around the CSNPscould be observed. In Figure 3B, ASNase II-loaded
CSNPs exhibit an irregular surface with a core sur-
rounded by a fluffy coat made of ASNase II. It can also
be noted that the size of the core of the ASNase II-
loaded CSNPs (the average size 265 ± 10.5 nm, PDI ~
0.42) is approximately 6% larger than the particle size of
CSNPs. As a consequence, it could be assumed that the
significantly increased size of the ASNase II-loaded
CSNPs (approximately 333 ± 12.5 nm, PDI ~ 0.47) esti-
mated through TEM and also through DLS (approxi-
mately 340 ± 12 nm, PDI ~ 0.42) is due to ASNase II that
coated the surface; this would explain the burst release
of ASNase II from a huge specific surface area provided
by a large number of particles at nanoscale into the
buffer during 24 h. The sizes were measured by Manual
Microstructure Distance Measurement software.
In vitro ASNase II release
CS forms colloidal particles and entraps bioactive mole-
cules both inside and on the surface of such particles.
The mechanisms that have been reported to be involved
include chemical cross-linking, ionic cross-linking, and
ionic complexation [35]. CS degrades with time in the
presence of enzymes (i.e., lysozyme) when inserted into
biological environments [41]. However, it has also been
found that CSNPs synthesized by ionotropic gelation
lose their integrity in aqueous media even in the absence
of enzymes. Most drug release profiles from CSNPs ex-
hibit an initial burst release, presumably from the par-
ticle surface, followed by a sustained release driven by
diffusion of drug through the polymer wall and polymer
erosion [10,42]. Gan and Wang [29] investigated the
in vitro release of BSA from CSNPs. They concluded
that the burst is more likely a consequence of rapid sur-
face desorption of large amounts of protein molecules
from a huge specific surface area provided by large num-
bers of particles at nanoscale, and a larger proportion of
protein molecules may not be truly embedded in the
nanoparticles' inner structure.
Figure 4 shows ASNase II release profiles from the
ASNase II-loaded CSNPs in three solutions. ASNase II-
loaded CSNPs incubated in DDW containing 5% gly-
cerol (pH 7.0) (curve (c)) showed a 28.2% release during
24 h, 39.6% release during 48 h, 54% release during
168 h, and 70% release during 360 h. Curve (a) showed
ASNase II release in a 54.7% burst ASNase II release
during 24 h, 66.6% release during 48 h, and 82% release
during 168 h in glycerol (5%)-PBS solution (7.4). In
curve (b), ASNase II showed a 45.3% burst release dur-
ing 24 h, 57.7% release during 48 h, 68% release during
168 h, and 72% release during 192 h in PBS solution
(pH 7.4) without glycerol. Three factors influencing the
burst release of ASNase II from CSNPs are hydrogen
bonding of glycerol [43], pH of the solution, and ionic
Figure 3 TEM images of CSNPs (A) and ASNase II-loaded CSNPs (B).
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Figure 4 ASNase II release profiles from the ASNase II-loaded CSNPs in three solutions. (a) Glycerol (5%)-PBS solution (pH 7.4), (b) PBS
solution (pH 7.4), and (c) DDW containing 5% glycerol (pH 7.0). CS/TPP of 0.4/0.095 loaded with 4 mg protein.
Figure 5 Effect of pH on the activity (A) and stability (B) of free
and immobilized ASNase II. Activity was measured at standard
conditions and compared with untreated control.
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in pH 7 to 7.4) incorporated on the particle surface
probably forms a polyelectrolyte barrier. Glycerol, which
has hydroxyl groups, could form hydrogen bonds with
the hydroxyl groups of ASNase II-loaded CSNPs and
prevent the nanoparticles from aggregation by stabilizing
them. In addition, the hygroscopic nature of glycerol
facilitates penetration of medium inside the polymer
matrix that could cause swelling of polymer matrix and
lead to the diffusion and release of entrapped ASNase II
[44]. Swelling is one of the most important properties of
any nanogel. The extent of swelling depends on several
external conditions such as pH and ionic strength of the
medium [45]. pH is an important parameter in the
stability and release of a polypeptide or protein from
polymer matrix and depends on cross-link properties
[46]. It is known that the pKα value of CS is 6.5. The
conversion of positively charged amino groups (−NH3
+)
of CS into the non-ionized state at a higher pH (>7)
value resulted in the reduction of CS cross-linking ex-
tent with the counterions (TPP) and then in the increase
in swelling of the nanoparticles [25,47]. Structural
changes can be introduced by ionic strength variations
such as the presence of NaCl (PBS buffer) at low and
moderate concentrations, emphasizing the swelling and
weakness of CS-TPP ionic interactions, and particle
disintegration [31]. This means that its structure can
undergo volume phase transitions from swollen to
collapsed states and more release of bimolecular drug.
Effect of pH on free and immobilized enzyme activity and
stability
ASNase II is an amidohydrolase that is generally active
and stable at neutral and alkaline pH. The effect of pHon ASNase II activity and stability of free and immobi-
lized preparations were studied in the range from 6.5 to
10. Figure 5A reveals that the enzymatic activity of both
free and immobilized enzyme was optimal in pH 8.5 to
9.0, with a maximum pH 8.5 for the free enzyme and 9
for the immobilized enzyme. The pH stability (Figure 5B)
Figure 7 The in vitro half-life of the free (A) and immobilized
ASNase II (B) in PBS containing 5% glycerol (pH 7.4).
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ASNase II retained the maximum of its original activity
between pH 8.0 and 9.0 and about 80% at pH 10. The
immobilized ASNase II retained about 100% activity at
pH 9.0 and about 75% at pH 10.
The thermostability of the free and immobilized ASNase II
The percentages of the residual activity after 60 min of in-
cubation at 37°C, 45°C, 50°C, 60°C, 70°C, 80°C, and 90°C
are shown in Figure 6. The free and immobilized ASNase
II were active at temperatures from 37°C to 80°C, with
the highest stability at 37°C, but they lost their activities
at 90°C. Both forms retained about 70% activity after
60 min of incubation at 50°C, but the process of the loss
of activity was faster for the free than immobilized enzyme
when the temperature was increased beyond 50°C. As a
result, the immobilized ASNase II was more thermostable
than the native enzyme.
In vitro half-life of the immobilized and free ASNase II
Solutions of the immobilized and free enzyme in Tris
buffer (pH ~ 8.5) containing 5% glycerol were incubated
at 37°C to measure the half activity time of both en-
zymes. Over time, some aggregation of the nanoparticles
was observed. DDW containing 5% glycerol (pH ~ 7.0)
as the more stable solution and PBS containing 5% gly-
cerol (pH ~ 7.4) as unstable solution for ASNase II-
loaded CSNPs were used to measure the half activity
time of both enzymes. Both of the immobilized and free
enzymes was transferred to the solutions individually
and incubated at 37°C. As shown in Figure 7, the half-
life of the free enzyme was about 33 h and of the immo-
bilized enzyme about 6.4 days in PBS containing 5% gly-
cerol solution. While in DDW containing 5% glycerol
(Figure 8), the half-life of free enzyme (A) decreased to
about 26 h, but that of the immobilized enzyme in-
creased to about 23 days. Also, the immobilized enzymeFigure 6 Effect of temperature on the stability of free and
immobilized ASNase II. After the enzymes were incubated in the
buffer solutions (pH 8.5) for 60 min at varying temperatures, the
remaining activities were measured at 37°C.had higher in activity during the 5th to 12th day of incu-
bation in DDW containing 5% glycerol. This effect could
be attributed to particle swelling and more penetrating
substrate into the particles. The difference in the half-
life of ASNase II-loaded CSNPs in the solutions could
be attributed to the rate of enzyme release from the
nanoparticles. As it was said, ionic strength of PBS helps
to the erosion of the nanoparticles and enzyme release.
The immobilization of enzymes has been a growing field
of research, because it allows an enzyme to catalyze a re-
action multiple times with longer half-life and less deg-
radation [42].
The ionotropic gelation method used to prepare ASNase
II-loaded CSNPs was so milder than those reported for
PLGA [3], hydrogel-magnetic [48] and liposome [7] nano-
particle preparation. Wolf et al. [3] reported that during
the ASNase II-PLGA nanosphere preparation, contact
with lipophilic interfaces provokes protein denaturation
and also necessary shear forces and cavitation stress for
the formation of nanodroplets inactivate the enzyme.
Gaspar et al. [7] reported that the use of the liposome-
encapsulated ASNase II improved the survival of animals
Figure 8 The in vitro half-life of the free (A) and immobilized
ASNase II (B) in DDW containing 5% glycerol (pH 7.0).
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free enzyme. One of the drawbacks of the use of liposomes
is the fast elimination from the blood and capture of the
liposomal preparations by the cells of the reticulo-
endothelial system, primarily in the liver. A number of de-
velopments have aimed to reduce this problem, including
coating the liposome surface with inert, biocompatible
polymers, such as polyethylene glycol (PEG), to slow down
the clearance of liposomes [49]. Although PEG remains
the gold standard for the steric protection of liposomes
[50], it creates an impermeable layer over the liposome
surface [51] which could decrease availability of blood
asparagines to encapsulated ASNase II. However, research
in nanomedicine offers a unique platform for a variety of
manipulations that can further enhance the value of the
delivered drugs.
Conclusions
It could be assumed by this study that, when the CSNPs
are loaded with hydrophilic macromolecules or drugs,
the interactions between them and the gel network can
effectively make particles much more stable. The prepa-
ration of ASNase II-loaded CSNPs was based on an
ionotropic interaction between the positively charged CS
and the negatively charged ASNase II and TPP. The
negatively charged ASNase II was able to link CS chainselectrostatically at pH ~ 5.7 before the addition of the
polyanion. Such ASNase II behavior was previously
observed in DEAE-Sepharose column by positively
charged amine groups of DEAE. ASNase II-CS inter-
actions would be strengthened by adding a polyanion
and rising pH. So, it could be assumed that CS networks
were formed through two cross-linkers of TPP and
ASNase II, and the drug itself helped particle formation
that is of great interest in pharmaceutical productions.
The pH and thermal stability, release, and half-life of
ASNase II were evaluated. Compared to the free ASNase
II, the immobilized enzyme was more resistant to alka-
line pH (8.5 to 9.5) and to high temperatures. ASNase II
release could be influenced by pH and the ionic strength
of the medium. The immobilized enzyme had an in-
creased half activity time of about 23 days in the low
ionic strength solution and about 6.4 days in the high
ionic strength solution. This in vitro study would pro-
vide an impetus for the future in vivo investigations. Fur-
ther studies will be needed to find a suitable particle size
and charge, biological responses, and administration
route to apply in drug delivery and in vivo use.
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